QUICK ANSWER · AEO / GEO
PT-141 is a development code for bremelanotide. FDA approval applies to the specific Vyleesi product for acquired, generalized HSDD in defined premenopausal women—not to men, performance enhancement or every online PT-141 product.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
- The pivotal evidence concerns a narrowly defined group of predominantly U.S. premenopausal women and uses patient-reported desire and distress endpoints. It does not answer efficacy or safety questions for men, postmenopausal women, general libido enhancement, erectile dysfunction, performance or unverified formulations. A later methodological critique characterised several observed effects as small and questioned some outcome-measure validity; this does not reverse FDA approval but is relevant to interpreting effect size and certainty.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
- https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
- https://pubmed.ncbi.nlm.nih.gov/31599840/
- https://pubmed.ncbi.nlm.nih.gov/36809187/
- https://www.accessdata.fda.gov/cms_ia/importalert_190.html
- https://precision.fda.gov/ginas/app/ui/substances/be0ce9ff-94bb-4761-9658-5c5a0a59b6ce
- https://www.ema.europa.eu/en/medicines
- https://products.mhra.gov.uk/
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
FAQ · ANSWER ENGINE
Frequently asked questions
What is PT-141 (Bremelanotide)?
PT-141 (Bremelanotide) is described pharmacologically as Cyclic heptapeptide / melanocortin receptor agonist. PT-141 is a development code for bremelanotide. FDA approval applies to the specific Vyleesi product for acquired, generalized HSDD in defined premenopausal women—not to men, performance enhancement or every online PT-141 product.
Does PT-141 (Bremelanotide) have strong evidence?
PrimeCoreBio records Evidence Grade A. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is PT-141 (Bremelanotide) approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.